In a SEC filing dated Sunday, Incyte, which is both incorporated and headquartered in Delaware, indicated the payment ...

By Jennifer Rigby LONDON (Reuters) -Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it ...

Roche is among several drugmakers to announce large-scale U.S. investments in response to Trump's push to onshore ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the launch of the second edition Health Equity ...

PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire ...

The Abu Dhabi Public Health Centre (ADPHC) has signed a Memorandum of Understanding (MoU) with Novartis Middle East FZE ...

LONDON, May 12 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health ...